Abstract
A bispecific antibody directed to T and B cells (CD3×CD19 bsAb) was daily infused intravenously in escalating doses from 10 μg up to 5 mg in three patients with chemotherapy-resistant non-Hodgkin lymphoma; in this way we aimed to activate T cells to kill the malignant B cells. Only limited toxicity was observed, consisting of moderate fever preceded by chills or shivers and mild thrombocytopenia. No human anti-(mouse Ig) antibodies were found. Pharmacokinetics showed at 1/2 of 10.5 h with peak levels of 200–300 ng/ml after infusion of 2.5 mg bsAb. bsAb in serum was functionally active in vitro. After bsAb infusion a rise in serum tumour necrosis factor α was observed, accompanied by an increase in soluble CD8 and to some extent in soluble interleukin-2 receptor (IL-2R), but not in interferon γ, IL-4 or soluble CD4. No evidence was found for monocyte activation (no increases in IL-6, IL-8 or IL-1ß in serum). No gross changess in histology or number of IL-2R+, CD4+ or CD8+ cells were found in the lymph nodes after therapy, but one patient showed activated CD8+ T cells within the tumour nodules. In conclusion, after intravenously administered CD3×CD19 bsAb only moderate toxicity was found, probably due to CD8+ T cell activation and cytokine release, without CD4+ T cell activation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002
Segal DM, Qian JH, Mezzanzanica D, Garrido MA, Titus JA, George AJT, Jost CR, Perez P, Wunderlich JR (1992) Targeting of anti-tumor responses with Bispecific antibodies. Immunobiology 185:390
Beun GDM, Velde CJH van de, Fleuren GJ (1994) T-cell based cancer immunotherapy: direct or redirect tumor-cell recognition. Immunol Today 15:11
Nitta T, Sato K, Yagita H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368
Bolhuis RLH, Lamers CHJ, Goey SH, Eggermont AMM, Trimbos JBMZ, Stoter G, Lanzavecchia A, Re E de, Miotti S, Raspagliesi F, Rivoltini L, Colnaghi MI (1992) Adoptive immunotherapy of ovarian carcinoma with Bs-Mab-targeted lymphocytes: a multi-center study. Int J Cancer Suppl 7:78
Tibben JG, Boerman OC, Claessens RAMJ (1993) Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab)2. J Natl Cancer Inst 85:1003
Uckun FM, Ledbetter JA (1988) Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Ac Sci USA 85:8603
Haagen IA, Griend R van de, Clark M, Geerars A, Bast B, Gast GC de (1992) Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19). Clin Exp Immunol 90:368
Haagen IA, Geerars AJ, Lau WB de, Clark MR, Griend RJ van de, Bast BJEG, Gast GC de (1994) Killing of autologous Blineage malignancy using CD3×CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 84:556
Haagen IA, Lau WBM de, Bast BJEG, Geerars AJG, Clark MR, GAst GC de (1994) Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother 39:391
Demanet C, Brissinck J, Mechelen Mv, Loe O, Thielemans K (1991) Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anit-idiotype×anti-CD3). J Immunol 147:1091
Brissinck J, Demanet C, Moser M, Leo O, Thielemans K (1991) Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol 147:4019–4026
Weiner GJ, Hillstrom JR (1991) Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147:4035
Clark MR, Waldmann H (1987) T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J Natl Cancer Inst 79:1393
Clark MR, Bindon C, Dyer M, Friend P, Hale G, Cobbold R, Calne H, Waldmann H (1989) The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur J Immunol 19:381
Vroom TM, Scholte G, Ossendorp F, Borst J (1991) Tissue distribution of human λδ T cells: no evidence for general epithelial tropism. J Clin Pathol 44:1012
Hekman A, Honselaar A, Vuist WMJ, Sein JJ, Rodenhuis S, Bokkel Huinink WW ten, Somers R, Rumke Ph, Melief CJM (1991) Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 32:364
Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL (1989) Soluble CD8 during T cell activation. J Immunol 142:224
Norment AM, Lonberg N, Lacy E, Littman DR (1989) Alternatively spliced mRNA encodes a secreted form of human CD8a. Characterization of the human CD8a gene. J Immunol 142:3312
Robb RJ, Kutny RM (1987) Structure function relationships for the IL-2 receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol 139:855
Huizinga TWG, Van der Schoot CE, Jost C, Klaassen R, Kleijer M, Von dem Borne AEGK, Roos D, Tetteroo PAT (1988) The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 333:667
Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA (1991) Activation of T lymphocytes in Dengue virus infections. J Clin Invest 88:1473
Sawada S, Sugai A, Lyma S, Takei M, Paredas E, Hayama T, Nishinarita S, Hosokawa Y, Horie T, Obara T (1992) Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome. Am J Med 92:134
Symons JA, McCulloch JF, Wood NC, Duff GW (1991) Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol 60:72
Beguin Y, Lapertz S, De Groote D, Igot D, Malaise M, Fillet G (1993) Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia. Leukemia 7:2019
Krutmann J, Kirnbauer R, Köck A, Schwarz T, Schöpf E, May LT, Sehgal PB, Luger TA (1990) Cross-linking Fc receptors on monocytes triggers IL-6 production: role in anti-CD3-induced T cell activation. J Immunol 145:1337
Yoshimura TY, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84:9233
Peters PM, Ortaldo JR, Shalaby MR, Svedersky LP, Nedwin GE, Bringman TS, Hass PE, Aggarwal BB, Herberman RB, Goeddel DV, Palladino MA (1986) Natural killer-sensitive targets stimulate production of TNF-α but not TNF-β (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol 137:2592
Haagen I-A, Geerars AJG, De Lau WBM, Bast EJEG, de Gast GC (1995) The efficacy of CD3×CD19 bsAb in a clonogenic assay; the effect of repeated addition of bispecific antibody and IL-2. Blood (in press)
Mueller DL, Jenkins MK, Schwartz RH (1989) Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7:445
Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM (1994) Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261
June CH, Ledbetter JA, Linsley PS, Thompson CB (1990) Role of the CD28 receptor in T-cell activation. Immunol Today 11:211
Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H (1993) Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3×CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803
Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, Fliedner V von, Diehl V, Tesch (1993) Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 53:4310
Weiner GJ (1992) Bispecific IgG and IL-2 therapy of a syngenic B-cell lymphoma in immunocompetent mice. Int J Cancer 7:63
Nakajima F, Khanna A, Xu G, Lagman M, Haschemeyer R, Mouradian J, Wang JC, Stenzel KH, Rubin AL, Suthanthiran M (1994) Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. Proc Natl Acad Sci USA 91:7889
Kroesen BJ, Buter J, Sleijfer DTh, Jansen RAJ, Graaf WTA van der, The TH, Leij L de, Mulder NH (1994) Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Caner 70:652
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Gast, G.C., Haagen, IA., van Houten, A.A. et al. CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40, 390–396 (1995). https://doi.org/10.1007/BF01525390
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01525390